Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked higher than
85% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. ORMP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ORMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.06  Med: 10000.00 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 34.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -33.67
ORMP's ROE (%) is ranked lower than
52% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. ORMP: -33.67 )
Ranked among companies with meaningful ROE (%) only.
ORMP' s ROE (%) Range Over the Past 10 Years
Min: -8090  Med: -75.21 Max: -31.7
Current: -33.67
-8090
-31.7
ROA (%) -32.22
ORMP's ROA (%) is ranked lower than
55% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ORMP: -32.22 )
Ranked among companies with meaningful ROA (%) only.
ORMP' s ROA (%) Range Over the Past 10 Years
Min: -468.93  Med: -66.23 Max: -30.04
Current: -32.22
-468.93
-30.04
ROC (Joel Greenblatt) (%) -105.74
ORMP's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. ORMP: -105.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ORMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -313200  Med: -310.63 Max: 5234
Current: -105.74
-313200
5234
EBITDA Growth (3Y)(%) 8.80
ORMP's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ORMP: 8.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ORMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.8  Med: 4.15 Max: 57
Current: 8.8
-10.8
57
EPS Growth (3Y)(%) 5.60
ORMP's EPS Growth (3Y)(%) is ranked higher than
63% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ORMP: 5.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ORMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25  Med: 2.30 Max: 183.6
Current: 5.6
-25
183.6
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.13
ORMP's P/B is ranked lower than
59% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ORMP: 3.13 )
Ranked among companies with meaningful P/B only.
ORMP' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 28.2
Current: 3.13
0
28.2
Current Ratio 11.65
ORMP's Current Ratio is ranked higher than
79% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ORMP: 11.65 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 7.18 Max: 67.68
Current: 11.65
0.13
67.68
Quick Ratio 11.65
ORMP's Quick Ratio is ranked higher than
80% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. ORMP: 11.65 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 7.18 Max: 67.68
Current: 11.65
0.13
67.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.68
ORMP's Price/Net Cash is ranked lower than
86% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ORMP: 27.68 )
Ranked among companies with meaningful Price/Net Cash only.
ORMP' s Price/Net Cash Range Over the Past 10 Years
Min: 2.58  Med: 12.02 Max: 139.2
Current: 27.68
2.58
139.2
Price/Net Current Asset Value 5.12
ORMP's Price/Net Current Asset Value is ranked higher than
58% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. ORMP: 5.12 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ORMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.56  Med: 8.17 Max: 94.5
Current: 5.12
2.56
94.5
Price/Tangible Book 3.14
ORMP's Price/Tangible Book is ranked higher than
60% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ORMP: 3.14 )
Ranked among companies with meaningful Price/Tangible Book only.
ORMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 7.97 Max: 75.6
Current: 3.14
2.19
75.6
Price/Projected FCF 15.62
ORMP's Price/Projected FCF is ranked lower than
83% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 3.23 vs. ORMP: 15.62 )
Ranked among companies with meaningful Price/Projected FCF only.
ORMP' s Price/Projected FCF Range Over the Past 10 Years
Min: 6.53  Med: 12.05 Max: 23.33
Current: 15.62
6.53
23.33
Earnings Yield (Greenblatt) (%) -10.21
ORMP's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ORMP: -10.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ORMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -666.7  Med: 0.00 Max: 9.3
Current: -10.21
-666.7
9.3

More Statistics

EPS $ -0.69
Beta0.72
Short Percentage of Float6.04%
52-Week Range $3.71 - 10.74
Shares Outstanding(Mil)13.10

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Oramed to Present at the BIO CEO & Investor Conference Feb 04 2016
ORAMED PHARMACEUTICALS INC. Financials Jan 16 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure Jan 14 2016
Oramed reports 1Q loss Jan 13 2016
Oramed reports 1Q loss Jan 13 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jan 13 2016
Oramed Pharma (ORMP): Great Potential for its Unique Protein Oral Delivery (POD) Platform Jan 12 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure Jan 06 2016
Oramed Pharmaceuticals’ Shareholder Letter Jan 06 2016
Oramed Pharmaceuticals' Shareholder Letter Jan 06 2016
Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in... Dec 29 2015
Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in... Dec 29 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Dec 28 2015
$50 Million Plus Royalties Deal Indicates Blockbuster Future for Oramed's Oral Insulin Dec 01 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 30 2015
Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal Nov 30 2015
Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China Nov 30 2015
Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China Nov 30 2015
Israel's Oramed gets $50 mln China licensing, investment deal Nov 30 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Nov 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK